A study to evaluate TCZ in patients with severe COVID-19 Pneumonia

A Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Tocilizumab In Patients With Severe Covid-19 Pneumonia

Status: Closed

Type: Interventional

Funder: F. Hoffmann-La Roche Ltd

Sponsor: F. Hoffmann-La Roche Ltd

CI: –

IRAS-Number: 282099

CPMS-ID: 45484

Approval Date: 26 March 2020

Description:

This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of tocilizumab (TCZ) compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with severe COVID-19 pneumonia.